Relatório de Análise de Tamanho, Participação e Tendências do Mercado Europeu de Tratamento de Cólicas Menstruais – Visão Geral do Setor e Previsão até 2032

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista Relatório de amostra grátis Relatório de amostra grátis Consulte antes Comprar Consulte antes  Comprar agora Comprar agora

Relatório de Análise de Tamanho, Participação e Tendências do Mercado Europeu de Tratamento de Cólicas Menstruais – Visão Geral do Setor e Previsão até 2032

  • Pharmaceutical
  • Publish Reports
  • Jan 2021
  • Europe
  • 350 Páginas
  • Número de tabelas: 491
  • Número de figuras: 43

Contorne os desafios das tarifas com uma consultoria ágil da cadeia de abastecimento

A análise do ecossistema da cadeia de abastecimento agora faz parte dos relatórios da DBMR

Europe Menstrual Cramps Treatment Market

Tamanho do mercado em biliões de dólares

CAGR :  % Diagram

Chart Image USD 1.48 Billion USD 2.55 Billion 2024 2032
Diagram Período de previsão
2025 –2032
Diagram Tamanho do mercado (ano base )
USD 1.48 Billion
Diagram Tamanho do mercado ( Ano de previsão)
USD 2.55 Billion
Diagram CAGR
%
Diagram Principais participantes do mercado
  • Bayer AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Teva Pharmaceuticals USA Inc.
  • Sanofi

Segmentação do mercado europeu de tratamento de cólicas menstruais, por tipo (dismenorreia primária, dismenorreia secundária), tipo de tratamento (medicação, terapia, cirurgia, outros), modo de prescrição (sem receita, prescrição), via de administração (oral, parenteral, implantes, outros), usuário final (hospitais, centros especializados, centros cirúrgicos ambulatoriais, outros), canal de distribuição (farmácias, vendas no varejo, licitação direta, outros), país (Alemanha, França, Itália, Reino Unido, Espanha, Holanda, Rússia, Suíça, Turquia, Bélgica, Áustria, Noruega, Hungria, Lituânia, Irlanda, Polônia, resto da Europa) Tendências e previsões do setor até 2032

Mercado Z de Tratamento para Cólicas Menstruais

Tamanho do mercado de tratamento para cólicas menstruais

  • O tamanho do mercado europeu de tratamento de cólicas menstruais foi avaliado em US$ 1,48 bilhão em 2024  e deve atingir  US$ 2,55 bilhões até 2032 , com um CAGR de 7,10% durante o período previsto.
  • O crescimento do mercado europeu de tratamento para cólicas menstruais é amplamente impulsionado pela crescente prevalência de dismenorreia e pela conscientização crescente sobre a saúde menstrual, levando a uma maior demanda por opções de tratamento eficazes em toda a região.
  • Além disso, a crescente demanda dos consumidores por soluções seguras, eficientes e prontamente disponíveis para o alívio da dor menstrual está consolidando diversas modalidades de tratamento, incluindo medicamentos de venda livre e métodos não farmacológicos avançados, como a escolha moderna. Esses fatores convergentes estão acelerando a adoção de soluções para o tratamento da cólica menstrual, impulsionando significativamente o crescimento do setor.

Análise de Mercado para Tratamento de Cólicas Menstruais

  • Os tratamentos para cólicas menstruais, que oferecem alívio da dor e do desconforto associados à menstruação, são componentes cada vez mais vitais do gerenciamento da saúde da mulher devido à sua maior eficácia, às variadas opções de administração e ao crescente foco no atendimento personalizado.
  • A crescente demanda por tratamentos para cólicas menstruais é alimentada principalmente pela prevalência generalizada de dismenorreia, pela conscientização crescente sobre a saúde menstrual entre os consumidores e pela preferência crescente por soluções eficazes e acessíveis para o alívio da dor.
  • A Europa detém uma fatia significativa do mercado de tratamento de cólicas menstruais, caracterizado pelo aumento do consumo de medicamentos de venda livre (OTC) e pelos crescentes investimentos em assistência médica, com países como Alemanha e Reino Unido experimentando um crescimento substancial devido à maior conscientização e à grande procura de tratamento pela população feminina.
  • Espera-se que a região da Ásia-Pacífico seja a região de crescimento mais rápido no mercado de tratamento de cólicas menstruais durante o período previsto, devido à crescente urbanização, ao aumento da renda disponível e às crescentes campanhas de conscientização relacionadas à saúde da mulher.
  • Espera-se que o segmento de medicamentos, particularmente os anti-inflamatórios não esteroidais (AINEs), domine o mercado de tratamento de cólicas menstruais, impulsionado por sua reputação estabelecida de eficácia, ampla disponibilidade e baixo custo como terapia de primeira linha para dismenorreia.

Escopo do Relatório e Segmentação do Mercado de Tratamento de Cólicas Menstruais       

Atributos

Insights sobre o mercado de chaves de fechadura inteligente

Segmentos abrangidos

  • Por tipo: Dismenorreia primária, Dismenorreia secundária
  • Por tipo de tratamento: medicação, terapia, cirurgia, outros
  • Por modo de prescrição: sem receita, com receita
  • Por via de administração: oral, parenteral, implantes, outros
  • Por usuário final: hospitais, centros especializados, centros cirúrgicos ambulatoriais, outros
  • Por canal de distribuição: Farmácias, Vendas no varejo, Licitação direta, Outros

Países abrangidos

América do Norte

  • NÓS
  • Canadá
  • México

Europa

  • Alemanha
  • França
  • Reino Unido
  • Holanda
  • Suíça
  • Bélgica
  • Rússia
  • Itália
  • Espanha
  • Peru
  • Resto da Europa

Ásia-Pacífico

  • China
  • Japão
  • Índia
  • Coréia do Sul
  • Cingapura
  • Malásia
  • Austrália
  • Tailândia
  • Indonésia
  • Filipinas
  • Resto da Ásia-Pacífico

Oriente Médio e África

  • Arábia Saudita
  • Emirados Árabes Unidos
  • África do Sul
  • Egito
  • Israel
  • Resto do Oriente Médio e África

Ámérica do Sul

  • Brasil
  • Argentina
  • Resto da América do Sul

Principais participantes do mercado

  • Bayer AG (Leverkusen, Alemanha)
  • GlaxoSmithKline plc (Londres, Reino Unido)
  • Pfizer Inc. (Nova York, EUA)
  • Teva Pharmaceuticals USA, Inc. (Parsippany, Nova Jersey, EUA)
  • Color Seven Co., Ltd. (Seul, Coreia do Sul)
  • Beurer GmbH (Ulm, Alemanha)
  • Mylan NV (Canonsburg, Pensilvânia, EUA)
  • Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Alemanha)
  • PMS4PMS, LLC (informações da sede não estão prontamente disponíveis)
  • Sanofi (Paris, França)
  • Nobelpharma Co., Ltd. (Informações da sede não disponíveis prontamente)
  • ObsEva (Genebra, Suíça)
  • Myovant Sciences Ltd. (Basileia, Suíça)
  • AbbVie Inc. (Norte de Chicago, Illinois, EUA)
  • BioElectronics Corporation (Frederick, Maryland, EUA)
  • LIVIA (informações da sede não estão prontamente disponíveis)
  • Alvogen (Pine Brook, Nova Jersey, EUA)
  • Cumberland Pharmaceuticals Inc. (Nashville, Tennessee, EUA)
  • Lupin Pharmaceuticals, Inc. (Baltimore, Maryland, EUA)
  • Janssen Pharmaceuticals, Inc. (Titusville, Nova Jersey, EUA)
  • Sun Pharmaceutical Industries Ltd. (Mumbai, Índia)

Oportunidades de mercado

  • Aumentando a conscientização e a aceitação de soluções para a saúde menstrual
  • Aumento das atividades de pesquisa e desenvolvimento para novas terapias

Conjuntos de informações de dados de valor agregado

Além dos insights sobre cenários de mercado, como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e principais participantes, os relatórios de mercado selecionados pela Data Bridge Market Research também incluem análises aprofundadas de especialistas, análises de preços, análises de participação de marca, pesquisas com consumidores, análises demográficas, análises da cadeia de suprimentos, análises da cadeia de valor, visão geral de matérias-primas/consumíveis, critérios de seleção de fornecedores, análise PESTLE, análise de Porter e estrutura regulatória.

Tendências de mercado para tratamento de cólicas menstruais

“Gestão personalizada da dor por meio de soluções de saúde digital com tecnologia de IA”

  • Uma tendência significativa e crescente no mercado europeu de tratamento de cólicas menstruais é a integração cada vez maior com plataformas de inteligência artificial (IA) e saúde digital. Essa fusão de tecnologias está aumentando significativamente a conveniência e o controle das usuárias sobre suas estratégias de gerenciamento da dor.
    • Por exemplo, aplicativos de monitoramento menstrual com tecnologia de IA, como Flo e Clue, integram-se perfeitamente aos sintomas relatados pelas usuárias e aos dados históricos do ciclo menstrual, permitindo prever períodos menstruais, ovulação e janelas férteis com maior precisão, e frequentemente oferecendo insights personalizados para o gerenciamento do desconforto associado. Da mesma forma, dispositivos vestíveis que utilizam tecnologias como TENS (Estimulação Elétrica Nervosa Transcutânea) ou terapia de calor estão se integrando a aplicativos inteligentes para oferecer programas personalizáveis ​​de alívio da dor.
  • A integração de IA no tratamento de cólicas menstruais permite recursos como o aprendizado dos padrões de dor da usuária para sugerir o momento ideal para o tratamento e fornecer alertas mais inteligentes com base na gravidade dos sintomas. Por exemplo, algumas terapias digitais utilizam IA para aprimorar as recomendações de alívio da dor ao longo do tempo e podem enviar alertas inteligentes caso padrões de dor incomuns ou intensos sejam detectados. Além disso, as plataformas de saúde digital oferecem às usuárias a facilidade de monitorar sintomas, a ingestão de medicamentos e fatores de estilo de vida, permitindo que elas entendam e gerenciem melhor sua jornada individual de saúde menstrual.
  • A integração perfeita de soluções baseadas em IA com ecossistemas de saúde digital mais amplos facilita o controle centralizado sobre vários aspectos do bem-estar menstrual. Por meio de uma única interface, as usuárias podem gerenciar suas estratégias de alívio da dor, além de monitorar o humor, os níveis de atividade e outros dados de saúde, criando uma abordagem unificada e automatizada para o gerenciamento da saúde menstrual.
  • Essa tendência em direção a sistemas de gerenciamento da dor mais inteligentes, intuitivos e interconectados está remodelando fundamentalmente as expectativas das usuárias em relação ao alívio do desconforto menstrual. Consequentemente, as empresas estão desenvolvendo soluções de saúde digital habilitadas por IA, com recursos como recomendações personalizadas automáticas para alívio da dor com base nos sintomas relatados e integração com outros aplicativos de bem-estar.
  • A demanda por tratamentos para cólicas menstruais que ofereçam integração perfeita de IA e saúde digital está crescendo rapidamente no mercado europeu, à medida que os consumidores priorizam cada vez mais conveniência, atendimento personalizado e funcionalidades abrangentes de autogerenciamento.

Dinâmica do mercado de tratamento para cólicas menstruais

Motorista

Necessidade crescente devido à crescente prevalência de dismenorreia e à maior conscientização sobre saúde

  • A prevalência crescente de cólicas menstruais (dismenorreia) entre mulheres, aliada à conscientização crescente e à discussão aberta sobre a saúde menstrual, é um fator significativo para o aumento da demanda por tratamentos eficazes para cólicas menstruais.
    • Por exemplo, nos últimos anos, empresas introduziram soluções não farmacológicas inovadoras, como dispositivos vestíveis de terapia térmica ou unidades TENS, com o objetivo de proporcionar alívio prático e sem medicamentos para a dor. Espera-se que tais avanços, realizados por empresas importantes, impulsionem o crescimento do setor de tratamento de cólicas menstruais no período previsto.
  • À medida que as pessoas se tornam mais conscientes do impacto da dor menstrual em suas vidas diárias e buscam melhores opções de alívio e tratamento, os tratamentos modernos oferecem recursos avançados, como alívio direcionado da dor, abordagens personalizadas e efeitos colaterais reduzidos, fornecendo uma alternativa ou complemento atraente aos métodos tradicionais.
  • Além disso, a crescente popularidade de abordagens de saúde holística e o desejo por bem-estar abrangente estão tornando os tratamentos para cólicas menstruais um componente integral dessas estratégias de saúde mais amplas, oferecendo integração perfeita com modificações no estilo de vida e práticas de autocuidado.
  • A conveniência de medicamentos de venda livre prontamente disponíveis, a acessibilidade a diversas opções terapêuticas e a capacidade de controlar os sintomas por meio de aplicativos de saúde digitais de fácil utilização são fatores-chave que impulsionam a adoção de tratamentos para cólicas menstruais. A tendência à autogestão e a crescente disponibilidade de diversas opções de tratamento contribuem ainda mais para o crescimento do mercado.

Restrição/Desafio

Preocupações com os efeitos colaterais e o estigma associados aos tratamentos

  • As preocupações em torno dos potenciais efeitos colaterais dos tratamentos farmacêuticos e o estigma social associado aos problemas de saúde menstrual representam um desafio significativo para uma penetração mais ampla no mercado. Como os tratamentos para cólicas menstruais frequentemente envolvem medicamentos ou terapias, eles podem estar associados a reações adversas ou à relutância em buscar ajuda devido a questões de privacidade, gerando ansiedade entre potenciais consumidores quanto à segurança e adequação dessas opções.
    • Por exemplo, a conscientização pública sobre os potenciais efeitos colaterais de certos medicamentos, ou a percepção de invasividade de algumas terapias, fez com que alguns consumidores hesitassem em adotar soluções de tratamento convencionais.
  • Abordar essas preocupações por meio de pesquisas robustas, comunicação clara dos benefícios versus riscos e desenvolvimento de terapias mais direcionadas é crucial para construir a confiança do consumidor. As empresas enfatizam seus rigorosos ensaios clínicos e programas de suporte ao paciente para tranquilizar potenciais compradores. Além disso, o custo relativamente alto de alguns regimes de tratamento avançados ou de longo prazo, ou políticas de reembolso insuficientes, podem ser uma barreira à adoção por consumidores sensíveis a preço, especialmente para aqueles que buscam atendimento especializado. Embora analgésicos básicos de venda livre sejam acessíveis, recursos premium, como dispositivos vestíveis avançados ou planos de terapia personalizados, geralmente têm um preço mais alto.
  • Embora o acesso a vários tratamentos esteja melhorando, a percepção do fardo do gerenciamento contínuo ou a preferência por alternativas não farmacológicas ainda podem dificultar a adoção generalizada, especialmente para aqueles que buscam abordagens mais naturais ou menos invasivas.
  • Superar esses desafios por meio de melhor educação do paciente, informações transparentes sobre os resultados do tratamento e o desenvolvimento de opções terapêuticas mais acessíveis e de menor custo será vital para o crescimento sustentado do mercado.

Escopo de mercado para tratamento de cólicas menstruais

O mercado é segmentado com base no tipo, tipo de tratamento, modo de prescrição, via de administração, usuário final e canal de distribuição.

  • Por tipo

Com base no tipo, o mercado europeu de tratamento para cólicas menstruais é segmentado em dismenorreia primária e dismenorreia secundária. Espera-se que o segmento de dismenorreia primária domine o mercado, visto que a maioria das pacientes apresenta sintomas de cólica primária ou leve, e apresenta alta prevalência em toda a Europa (variando de 52,4% a 85,7% em vários estudos). As pessoas frequentemente priorizam tratamentos para dismenorreia primária devido à sua ampla ocorrência e à disponibilidade de opções de alívio acessíveis. O mercado também observa uma forte demanda por tratamentos para dismenorreia primária devido à crescente conscientização sobre a saúde menstrual e ao foco crescente no controle eficaz da dor.

  • Prevê-se que o segmento da dismenorreia secundária apresente um crescimento significativo, impulsionado pelo aumento do diagnóstico de doenças subjacentes, como endometriose, miomas uterinos e adenomiose. À medida que as ferramentas de diagnóstico e a compreensão médica melhoram, mais casos de dismenorreia secundária são identificados, levando a uma demanda por soluções de tratamento direcionadas e, muitas vezes, mais complexas. A crescente prevalência de doenças como a endometriose em mulheres em toda a Europa também contribui para a crescente necessidade de tratamentos para dismenorreia secundária.

Por tipo de tratamento

Com base no tipo, o mercado europeu de tratamento para cólicas menstruais é segmentado em dismenorreia primária e dismenorreia secundária. Espera-se que o segmento de dismenorreia primária domine o mercado, visto que a maioria das pacientes apresenta sintomas de cólica primária ou leve, e apresenta alta prevalência em toda a Europa (variando de 52,4% a 85,7% em vários estudos). As pessoas frequentemente priorizam tratamentos para dismenorreia primária devido à sua ampla ocorrência e à disponibilidade de opções de alívio acessíveis. O mercado também observa uma forte demanda por tratamentos para dismenorreia primária devido à crescente conscientização sobre a saúde menstrual e ao foco crescente no controle eficaz da dor.

Prevê-se que o segmento da dismenorreia secundária apresente um crescimento significativo, impulsionado pelo aumento do diagnóstico de doenças subjacentes, como endometriose, miomas uterinos e adenomiose. À medida que as ferramentas de diagnóstico e a compreensão médica melhoram, mais casos de dismenorreia secundária são identificados, levando a uma demanda por soluções de tratamento direcionadas e, muitas vezes, mais complexas. A crescente prevalência de doenças como a endometriose em mulheres em toda a Europa também contribui para a crescente necessidade de tratamentos para dismenorreia secundária.

Por Modo de Prescrição

Com base no modo de prescrição, o mercado europeu de tratamento para cólicas menstruais é segmentado em medicamentos de venda livre (OTC) e com receita médica. Espera-se que o segmento de medicamentos de venda livre domine o mercado, impulsionado pela fácil acessibilidade e preço acessível de analgésicos como os AINEs. A tendência crescente de automedicação para dores menstruais leves a moderadas e a crescente conscientização das consumidoras sobre soluções prontamente disponíveis contribuem significativamente para a grande participação desse segmento.

Prevê-se que o segmento de medicamentos prescritos apresentará um crescimento substancial, impulsionado pelo aumento do diagnóstico de casos de dismenorreia grave ou secundária, que requerem medicamentos mais fortes ou terapias hormonais sob supervisão médica. O número crescente de mulheres que buscam aconselhamento médico profissional para dores menstruais persistentes ou debilitantes e os avanços em tratamentos prescritos direcionados são fatores-chave que contribuem para o crescimento deste segmento.

Por via de administração

Com base na via de administração, o mercado europeu de tratamento para cólicas menstruais é segmentado em oral, parenteral, implantes e outros. Espera-se que o segmento oral domine o mercado, principalmente devido à conveniência, familiaridade e ampla disponibilidade de medicamentos orais, como comprimidos e cápsulas. A administração oral continua sendo o método mais comum e preferido para o alívio da dor devido à sua facilidade de uso e rápida absorção.

Espera-se que os segmentos parenteral e de implantes apresentem crescimento, impulsionados pela necessidade de alívio mais rápido da dor em casos graves (parenteral) ou por tratamento de longo prazo e controle hormonal (implantes). Esses métodos oferecem benefícios como liberação prolongada de medicamentos e bypass do sistema digestivo, tornando-os adequados para necessidades específicas de pacientes ou condições em que a administração oral é menos eficaz.

Análise regional do mercado de tratamento de cólicas menstruais

  • Espera-se que a Europa detenha uma fatia significativa do mercado de tratamento para cólicas menstruais, impulsionada pela alta prevalência de dismenorreia entre a população feminina e pela infraestrutura avançada de saúde. Países como Alemanha, França e Reino Unido são importantes contribuintes para esse mercado, apresentando uma forte demanda por tratamentos de venda livre e com receita médica.
  • Os consumidores da região valorizam muito o alívio eficaz da dor, a facilidade de acesso e a crescente aceitação da busca por soluções médicas para o desconforto menstrual. Isso se soma a campanhas e iniciativas de conscientização cada vez mais intensas que promovem a saúde menstrual como um aspecto vital do bem-estar geral.
  • Essa ampla adoção é ainda apoiada por altos gastos com saúde, uma população bem informada e ativamente envolvida no gerenciamento de sua saúde e a crescente disponibilidade de diversas opções de tratamento, estabelecendo o gerenciamento abrangente da dor menstrual como uma abordagem preferida nos países europeus.

Visão geral do mercado de tratamento para cólicas menstruais na Alemanha

A Alemanha é um mercado líder na Europa para o tratamento de cólicas menstruais, impulsionado por uma alta conscientização sobre a saúde menstrual e um sistema de saúde robusto. Os consumidores alemães têm fácil acesso a medicamentos de venda livre e buscam aconselhamento médico profissional para o controle da dor menstrual. O mercado é ainda mais impulsionado por iniciativas contínuas de saúde pública e pela disponibilidade de uma ampla gama de opções de tratamento farmacológico e não farmacológico.

Visão geral do mercado de tratamento para cólicas menstruais na França

A França ocupa uma posição significativa no mercado europeu de tratamento de cólicas menstruais, impulsionada pelo aumento dos investimentos em saúde e pelo foco crescente na saúde da mulher. Há uma tendência crescente na França para combater a pobreza menstrual e ampliar o acesso a produtos de higiene menstrual, o que indiretamente apoia o mercado mais amplo de tratamento da dor menstrual. O mercado se beneficia tanto de soluções farmacêuticas tradicionais quanto de um interesse crescente em métodos sustentáveis ​​e alternativos de alívio da dor.

Visão geral do mercado de tratamento para cólicas menstruais no Reino Unido

O mercado britânico de tratamento para cólicas menstruais está em rápido crescimento, principalmente devido ao aumento da população feminina e à maior conscientização sobre problemas de saúde menstrual. Os consumidores no Reino Unido buscam cada vez mais soluções eficazes para o desconforto menstrual, o que leva a uma forte demanda por medicamentos convencionais e produtos inovadores. Iniciativas governamentais voltadas para a melhoria do acesso a produtos menstruais e à educação contribuem ainda mais para a expansão do mercado.

Participação no mercado de tratamento de cólicas menstruais

O setor de fechaduras inteligentes é liderado principalmente por empresas bem estabelecidas, incluindo:

  • Bayer AG (Alemanha)
  • GlaxoSmithKline plc (Reino Unido)
  • Pfizer Inc. (EUA)
  • Teva Pharmaceuticals USA, Inc. (EUA)
  • Color Seven Co., Ltd. (Coreia do Sul)
  • Beurer GmbH (Alemanha)
  • Mylan NV (EUA)
  • Boehringer Ingelheim International GmbH (Alemanha)
  • PMS4PMS, LLC
  • Sanofi (França)
  • Nobelpharma Co., Ltd.
  • ObsEva (Suíça)
  • Myovant Sciences Ltd. (Suíça)
  • AbbVie Inc. (EUA)
  • BioElectronics Corporation (EUA)
  • LÍVIA
  • Alvogen (EUA)
  • Cumberland Pharmaceuticals Inc. (EUA)
  • Lupin Pharmaceuticals, Inc. (EUA)
  • Janssen Pharmaceuticals, Inc. (EUA)
  • Sun Pharmaceutical Industries Ltd. (Índia)

Últimos desenvolvimentos no mercado europeu de tratamento de cólicas menstruais

  • Em março de 2025, a Samphire Neuroscience (Londres, Reino Unido), pioneira em neurotecnologia, lançou oficialmente o Nettle, seu dispositivo cerebral com certificação CE, projetado para aliviar os sintomas mentais e físicos associados à menstruação. Esta iniciativa reforça a dedicação da empresa em fornecer soluções inovadoras e não farmacológicas para o alívio da dor, adaptadas à crescente demanda europeia por tratamentos alternativos e tecnológicos para a saúde menstrual. Ao alavancar sua expertise em estimulação transcraniana por corrente contínua (ETCC), a Samphire Neuroscience não está apenas abordando o desconforto, mas também reforçando sua posição no mercado de femtech e terapias digitais em rápida expansão.
  • Em 2024, a Bayer AG (Leverkusen, Alemanha), líder europeia em produtos farmacêuticos, manteve estrategicamente seu foco no avanço dos tratamentos para dor pélvica associada à endometriose, uma causa significativa de dismenorreia secundária na Europa. Esse compromisso contínuo, exemplificado pela pesquisa e comercialização contínuas de produtos como Visanne, reforça a dedicação da empresa em fornecer soluções médicas eficazes e personalizadas para condições complexas de dor ginecológica. Ao alavancar sua ampla capacidade de P&D e sua sólida experiência farmacêutica, a Bayer AG não está apenas abordando a dor crônica, mas também reforçando sua posição dominante no setor de saúde da mulher, em rápida evolução.
  • Em 2024, o mercado europeu de tratamento de cólicas menstruais continuou estrategicamente seu foco no avanço de terapias naturais e não hormonais , impulsionado pela forte preferência do consumidor por suplementos de gengibre, cúrcuma, magnésio e ômega-3 - e pela crescente popularidade de adesivos de ervas e dispositivos de terapia de calor
  • Em 2025, o mercado europeu de tratamento de cólicas menstruais continuou estrategicamente seu foco em soluções vestíveis pioneiras integradas à IoT , como roupas íntimas com adesivos térmicos inteligentes e almofadas térmicas habilitadas para Bluetooth, projetadas para fornecer alívio direcionado durante a menstruação, impulsionando a adoção de dispositivos portáteis e conectados para gerenciamento da dor.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

4.1 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, PIPELINE ANALYSIS

5 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: REGULATIONS

6 PREMIUM INSIGHTS

6.1 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: ADOPTION RATE

6.1.1 DRIVERS AND BARRIERS FOR THE ADOPTIONS

6.2 MARKETING EXPENSES

6.3 PAYERS:

6.4 PHARMACIES COLD/HOT PADS MARKET SHARE:

7 EPIDEMIOLOGY

8 COVID-19 IMPACT ON EUROPE MENSTRUAL CRAMPS TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19

8.5 CONCLUSION

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 GROWING PREVALENCE OF DYSMENORRHEA

9.1.2 RISING TECHNOLOGICAL ADVANCEMENTS

9.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR DEVELOPING INNOVATIVE DRUGS AND THERAPIES

9.1.4 GOVERNMENT INITIATIVES WITH RESPECT TO WOMEN HEALTHCARE

9.1.5 INCREASING NUMBER OF TREATMENT OPTIONS

9.2 RESTRAINTS

9.2.1 PRODUCT RECALLS

9.2.2 LACK OF AWARENESS ABOUT REPRODUCTIVE HEALTH IN WOMEN

9.2.3 HIGH COST OF ENDOMETRIAL ABLATION AND HYSTERECTOMY

9.3 OPPORTUNITIES

9.3.1 RISE IN AWARENESS ABOUT DYSMENORRHEA

9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

9.3.3 RISING DISPOSABLE INCOME

9.4 CHALLENGES

9.4.1 TRADITIONAL FAMILY VALUE LEADING TO NO TREATMENT

9.4.2 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH LONG TERM TREATMENT

9.4.3 EFFECTIVENESS OF COMPLEMENTARY AND ALTERNATIVE THERAPIES

10 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE

10.1 OVERVIEW

10.2 PRIMARY DYSMENORRHEA

10.3 SECONDARY DYSMENORRHEA

11 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 FIRST LINE TREATMENT

11.2.1.1 Nonhormonal Therapy

11.2.1.1.1 Nonsteroidal Anti-Inflammatory Drugs

11.2.1.1.1.1 Ibuprofen

11.2.1.1.1.2 Naproxen

11.2.1.1.1.3 Celecoxib

11.2.1.1.1.4 Mefenamic Acid

11.2.1.1.1.5 Meclofenamate

11.2.1.1.2 Acetaminophen

11.2.1.2 Hormonal Replacement Therapy y

11.2.1.2.1 Combined Oral Contraceptives (Monophasic or Multiphasic)

11.2.1.2.1.1 Norethindrone/Ethinyl Estradiol

11.2.1.2.1.2 Extended-Cycle Oral Contraceptives

11.2.1.2.2 Extended-Cycle Oral Contraceptives

11.2.1.2.2.1 Levonorgestrel/Ethinyl Estradiol

11.2.1.2.2.2 Others

11.2.1.2.3 Other

11.2.1.2.3.1 Etonogestrel/Ethinyl Estradiol

11.2.1.2.3.2 Etonogestrel Implant

11.2.1.2.3.3 Levonorgestrel-Releasing Intrauterine System

11.2.1.2.3.4 Medroxyprogesterone Shot

11.2.1.3 Diuretic

11.2.1.3.1 Spironolactone

11.2.1.3.2 Ammonium Chloride

11.2.1.4 Antidepressants

11.2.2 SECOND LINE TREATMENT

11.2.2.1 Empiric GNRH Analogue or Antagonist Therapy

11.2.2.2 Ammonium Chloride

11.3 THERAPY

11.3.1 HEAT THERAPY

11.3.1.1 Patch

11.3.1.2 Wrap

11.3.1.3 Ceramic Belt Emitting Far-Infrared Radiation (FIR)

11.3.2 BEHAVIORAL COUNSELING

11.3.2.1 Desensitization-Based Procedures

11.3.2.2 Coping Strategies

11.3.2.3 Imagery

11.3.2.4 Hypnotherapy

11.3.2.5 Others

11.3.3 DIET AND VITAMINS

11.3.3.1 Vitamin E

11.3.3.2 Vitamin B

11.3.3.3 Vitamin D

11.3.3.4 Others

11.4 SURGERY

11.4.1 ENDOMETRIAL ABLATION

11.4.2 HYSTERECTOMY

11.5 OTHERS

12 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION

12.1 OVERVIEW

12.2 OVER THE COUNTER

12.3 PRESCRIPTION

13 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 ORAL

13.2.1 TABLETS

13.2.2 PILLS

13.2.3 CAPSULE

13.2.4 OTHERS

13.3 PARENTERAL

13.3.1 INTRAVENOUS

13.3.2 SUBCUTANEOUS

13.3.3 OTHERS

13.4 IMPLANTS

13.5 OTHERS

14 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CENTERS

14.4 AMBULATORY SURGICAL CENTERS

14.5 OTHERS

15 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 PHARMACIES

15.2.1 HOSPITAL

15.2.2 RETAIL

15.3 DIRECT TENDER

15.4 RETAIL SALES

15.5 OTHERS

16 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY GEOGRAPHY

16.1 EUROPE

16.1.1 GERMANY

16.1.2 FRANCE

16.1.3 U.K.

16.1.4 ITALY

16.1.5 NETHERLANDS

16.1.6 SPAIN

16.1.7 RUSSIA

16.1.8 SWITZERLAND

16.1.9 TURKEY

16.1.10 AUSTRIA

16.1.11 NORWAY

16.1.12 BELGIUM

16.1.13 HUNGARY

16.1.14 LITHUANIA

16.1.15 IRELAND

16.1.16 POLAND

16.1.17 REST OF EUROPE

17 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: EUROPE

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 GLAXOSMITHKLINE PLC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANLYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 ABBVIE INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 MYLAN N. V. (A PART OF VIATRIS INC.).

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENT

19.6 ALVOGEN

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BAYER AG

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 BEURER GMBH

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 BIOELECTRONICS CORPORATION

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 COLOR SEVEN CO., LTD.

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENTS

19.12 CUMBERLAND PHARMACEUTICALS INC.

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 LIVIA

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENTS

19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.15 MYOVANT SCIENCES LTD.

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.16 NOBELPHARMA CO., LTD.

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 OBSEVA

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 PFIZER INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENTS

19.19 PMS4PMS, LLC

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENT

19.2 SANOFI

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

19.21 SUN PHARMACEUTICAL INDUSTRIES LTD.

19.21.1 COMPANY SNAPSHOT

19.21.2 REVENUE ANALYSIS

19.21.3 PRODUCT PORTFOLIO

19.21.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Lista de Tabela

LIST OF TABLES

TABLE 1 MARKETING EXPENSES OF THE MARKET PLAYERS

TABLE 2 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 3 EUROPE PRIMARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 EUROPE SECONDARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 6 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 7 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 8 EUROPE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 EUROPE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 10 EUROPE FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 11 EUROPE NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 12 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 13 EUROPE HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 14 EUROPE COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 15 EUROPE EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 16 EUROPE OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 17 EUROPE DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 18 EUROPE SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 19 EUROPE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 EUROPE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 21 EUROPE HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 22 EUROPE BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 23 EUROPE DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 24 EUROPE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 EUROPE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 26 EUROPE OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 28 EUROPE OVER THE COUNTER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 EUROPE PRESCRIPTION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 31 EUROPE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 EUROPE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 33 EUROPE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 EUROPE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 35 EUROPE IMPLANTS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 EUROPE OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)

TABLE 38 EUROPE HOSPITALS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 EUROPE SPECIALTY CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 EUROPE AMBULATORY SURGICAL CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 EUROPE OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

TABLE 43 EUROPE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 EUROPE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 45 EUROPE DIRECT TENDER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 EUROPE RETAIL SALES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 EUROPE OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 51 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 52 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 53 EUROPE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 54 EUROPE FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 55 EUROPE NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 56 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 57 EUROPE HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 58 EUROPE COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 59 EUROPE EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 60 EUROPE OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 61 EUROPE DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 62 EUROPE SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 63 EUROPE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 64 EUROPE HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 65 EUROPE BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 66 EUROPE DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 67 EUROPE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 68 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 69 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 70 EUROPE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 71 EUROPE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 EUROPE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 75 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 77 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 78 ERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 79 GERMANY MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 80 GERMANY FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 81 GERMANY NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 82 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 83 GERMANY HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 84 GERMANY COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 85 GERMANY EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 86 GERMANY OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 87 GERMANY DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 88 GERMANY SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 89 GERMANY THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 90 GERMANY HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 91 GERMANY BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 92 GERMANY DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 93 GERMANY SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 94 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 95 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 GERMANY ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 GERMANY PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 98 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 100 GERMANY PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 101 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 103 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 104 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 105 FRANCE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 106 FRANCE FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 107 FRANCE NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 108 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 109 FRANCE HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 110 FRANCE COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 111 FRANCE EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 112 FRANCE OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 113 FRANCE DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 114 FRANCE SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 115 FRANCE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 116 FRANCE HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 117 FRANCE BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 118 FRANCE DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 119 FRANCE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 120 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 121 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 122 FRANCE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 123 FRANCE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 124 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 125 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 126 FRANCE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 127 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 128 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 129 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 130 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 131 U.K. MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 132 U.K. FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 133 U.K. NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 134 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 135 U.K. HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 136 U.K. COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 137 U.K. EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 138 U.K. OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 139 U.K. DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 140 U.K. SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 141 U.K. THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 142 U.K. HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 143 U.K. BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 144 U.K. DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 145 U.K. SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 146 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 147 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 148 U.K. ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 149 U.K. PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 150 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 151 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 152 U.K. PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 153 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 154 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 155 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 156 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 157 ITALY MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 158 ITALY FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 159 ITALY NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 160 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 161 ITALY HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 162 ITALY COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 163 ITALY EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 164 ITALY OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 165 ITALY DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 166 ITALY SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 167 ITALY THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 168 ITALY HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 169 ITALY BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 170 ITALY DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 171 ITALY SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 172 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 173 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 174 ITALY ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 175 ITALY PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 176 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 177 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 178 ITALY PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 179 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 180 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 181 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 182 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 183 NETHERLANDS MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 184 NETHERLANDS FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 185 NETHERLANDS NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 186 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 187 NETHERLANDS HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 188 NETHERLANDS COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 189 NETHERLANDS EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 190 NETHERLANDS OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 191 NETHERLANDS DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 192 NETHERLANDS SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 193 NETHERLANDS THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 194 NETHERLANDS HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 195 NETHERLANDS BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 196 NETHERLANDS DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 197 NETHERLANDS SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 198 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 199 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 200 NETHERLANDS ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 201 NETHERLANDS PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 202 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 203 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 204 NETHERLANDS PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 205 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 206 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 207 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 208 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 209 SPAIN MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 210 SPAIN FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 211 SPAIN NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 212 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 213 SPAIN HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 214 SPAIN COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 215 SPAIN EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 216 SPAIN OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 217 SPAIN DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 218 SPAIN SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 219 SPAIN THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 220 SPAIN HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 221 SPAIN BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 222 SPAIN DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 223 SPAIN SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 224 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 225 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 226 SPAIN ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 227 SPAIN PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 228 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 229 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 230 SPAIN PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 231 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 232 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 233 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 234 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 235 RUSSIA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 236 RUSSIA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 237 RUSSIA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 238 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 239 RUSSIA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 240 RUSSIA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 241 RUSSIA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 242 RUSSIA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 243 RUSSIA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 244 RUSSIA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 245 RUSSIA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 246 RUSSIA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 247 RUSSIA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 248 RUSSIA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 249 RUSSIA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 250 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 251 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 252 RUSSIA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 253 RUSSIA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 254 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 255 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 256 RUSSIA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 257 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 258 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 259 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 260 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 261 SWITZERLAND MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 262 SWITZERLAND FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 263 SWITZERLAND NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 264 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 265 SWITZERLAND HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 266 SWITZERLAND COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 267 SWITZERLAND EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 268 SWITZERLAND OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 269 SWITZERLAND DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 270 SWITZERLAND SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 271 SWITZERLAND THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 272 SWITZERLAND HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 273 SWITZERLAND BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 274 SWITZERLAND DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 275 SWITZERLAND SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 276 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 277 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 278 SWITZERLAND ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 279 SWITZERLAND PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 280 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 281 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 282 SWITZERLAND PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 283 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 284 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 285 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 286 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 287 TURKEY MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 288 TURKEY FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 289 TURKEY NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 290 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 291 TURKEY HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 292 TURKEY COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 293 TURKEY EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 294 TURKEY OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 295 TURKEY DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 296 TURKEY SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 297 TURKEY THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 298 TURKEY HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 299 TURKEY BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 300 TURKEY DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 301 TURKEY SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 302 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 303 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 304 TURKEY ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 305 TURKEY PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 306 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 307 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 308 TURKEY PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 309 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 310 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 311 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 312 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 313 AUSTRIA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 314 AUSTRIA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 315 AUSTRIA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 316 AUSTRIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 317 AUSTRIA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 318 AUSTRIA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 319 AUSTRIA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 320 AUSTRIA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 321 AUSTRIA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 322 AUSTRIA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 323 AUSTRIA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 324 AUSTRIA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 325 AUSTRIA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 326 AUSTRIA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 327 AUSTRIA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 328 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 329 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 330 AUSTRIA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 331 AUSTRIA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 332 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 333 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 334 AUSTRIA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 335 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 336 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 337 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 338 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 339 NORWAY MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 340 NORWAY FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 341 NORWAY NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 342 NORWAY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 343 NORWAY HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 344 NORWAY COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 345 NORWAY EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 346 NORWAY OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 347 NORWAY DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 348 NORWAY SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 349 NORWAY THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 350 NORWAY HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 351 NORWAY BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 352 NORWAY DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 353 NORWAY SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 354 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 355 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 356 NORWAY ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 357 NORWAY PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 358 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 359 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 360 NORWAY PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 361 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 362 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 363 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 364 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 365 BELGIUM MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 366 BELGIUM FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 367 BELGIUM NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 368 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 369 BELGIUM HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 370 BELGIUM COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 371 BELGIUM EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 372 BELGIUM OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 373 BELGIUM DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 374 BELGIUM SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 375 BELGIUM THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 376 BELGIUM HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 377 BELGIUM BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 378 BELGIUM DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 379 BELGIUM SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 380 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 381 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 382 BELGIUM ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 383 BELGIUM PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 384 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 385 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 386 BELGIUM PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 387 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 388 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 389 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 390 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 391 HUNGARY MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 392 HUNGARY FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 393 HUNGARY NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 394 HUNGARY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 395 HUNGARY HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 396 HUNGARY COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 397 HUNGARY EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 398 HUNGARY OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 399 HUNGARY DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 400 HUNGARY SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 401 HUNGARY THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 402 HUNGARY HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 403 HUNGARY BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 404 HUNGARY DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 405 HUNGARY SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 406 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 407 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 408 HUNGARY ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 409 HUNGARY PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 410 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 411 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 412 HUNGARY PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 413 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 414 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 415 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 416 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 417 LITHUANIA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 418 LITHUANIA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 419 LITHUANIA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 420 LITHUANIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 421 LITHUANIA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 422 LITHUANIA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 423 LITHUANIA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 424 LITHUANIA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 425 LITHUANIA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 426 LITHUANIA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 427 LITHUANIA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 428 LITHUANIA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 429 LITHUANIA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 430 LITHUANIA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 431 LITHUANIA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 432 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 433 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 434 LITHUANIA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 435 LITHUANIA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 436 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 437 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 438 LITHUANIA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 439 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 440 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 441 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 442 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 443 IRELAND MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 444 IRELAND FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 445 IRELAND NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 446 IRELAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 447 IRELAND HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 448 IRELAND COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 449 IRELAND EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 450 IRELAND OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 451 IRELAND DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 452 IRELAND SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 453 IRELAND THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 454 IRELAND HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 455 IRELAND BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 456 IRELAND DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 457 IRELAND SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 458 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 459 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 460 IRELAND ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 461 IRELAND PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 462 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 463 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 464 IRELAND PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 465 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 466 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 467 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 468 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 469 POLAND MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 470 POLAND FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 471 POLAND NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 472 POLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 473 POLAND HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 474 POLAND COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 475 POLAND EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 476 POLAND OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 477 POLAND DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 478 POLAND SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 479 POLAND THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 480 POLAND HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 481 POLAND BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 482 POLAND DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 483 POLAND SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 484 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 485 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 486 POLAND ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 487 POLAND PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 488 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 489 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 490 POLAND PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 491 REST OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

 

Lista de Figura

LIST OF FIGURES

FIGURE 1 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION

FIGURE 10 INCREASING PREVALENCE OF DYSMENORRHEA IS EXPECTED TO DRIVE THE EUROPE MENSTRUAL CRAMPS TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 11 PRIMARY DYSMENORRHEA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MENSTRUAL CRAMPS TREATMENT MARKET IN 2021 & 2028

FIGURE 12 PHARMACIES COLD/HOT PADS MARKET SHARE: 2020 (%)

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET

FIGURE 14 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020

FIGURE 15 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 16 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 17 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020

FIGURE 19 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020-2028 (USD MILLION)

FIGURE 20 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2021-2028)

FIGURE 21 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, 2020

FIGURE 23 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION 2020-2028 (USD MILLION)

FIGURE 24 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, CAGR (2021-2028)

FIGURE 25 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, LIFELINE CURVE

FIGURE 26 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 27 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 28 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 29 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020

FIGURE 31 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 32 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, CAGR (2021-2028)

FIGURE 33 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 35 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 36 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 37 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 39 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 40 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 41 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 42 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE (2021-2028)

FIGURE 43 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY SHARE 2020 (%)

 

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

O mercado é segmentado com base em Segmentação do mercado europeu de tratamento de cólicas menstruais, por tipo (dismenorreia primária, dismenorreia secundária), tipo de tratamento (medicação, terapia, cirurgia, outros), modo de prescrição (sem receita, prescrição), via de administração (oral, parenteral, implantes, outros), usuário final (hospitais, centros especializados, centros cirúrgicos ambulatoriais, outros), canal de distribuição (farmácias, vendas no varejo, licitação direta, outros), país (Alemanha, França, Itália, Reino Unido, Espanha, Holanda, Rússia, Suíça, Turquia, Bélgica, Áustria, Noruega, Hungria, Lituânia, Irlanda, Polônia, resto da Europa) Tendências e previsões do setor até 2032 .
O tamanho do Relatório de Análise de Tamanho, Participação e Tendências do Mercado foi avaliado em USD 1.48 USD Billion no ano de 2024.
O Relatório de Análise de Tamanho, Participação e Tendências do Mercado está projetado para crescer a um CAGR de 7.1% durante o período de previsão de 2025 a 2032.
Os principais players do mercado incluem Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Teva Pharmaceuticals USA Inc., Sanofi, AbbVie Inc. .
Testimonial